All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

How does MRD guide therapeutic decisions in ALL?

Sep 22, 2021

Bookmark this article

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Rachel Rau, Texas Children's Hospital, Houston, US. We asked, How does MRD guide therapeutic decisions in ALL? 

How does MRD guide therapeutic decisions in ALL?

Rau begins by outlining the two main modalities with which MRD is measured, multiple parameter flow cytometry or PCR. Rau goes on to explain when to test MRD and the correlation between a poor prognosis and a higher MRD. She discusses high risk patients in ALL and the possible treatment options for patients who are still MRD positive after consolidation. Finally, Rau highlights that the future may hold further investigation into more sensitive assays, to further risk stratify patients, such as the clonoSEQ assay.


More about...


Subscribe to get the best content related to ALL delivered to your inbox